Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Tim Cruise who wrote (153)	9/21/1999 11:20:00 AM
From: thebeach	Read Replies (1) \| Respond to of 356

Found it Tim,here it is: NEWS RELEASE TRANSMITTED BY CANADIAN CORPORATE NEWS FOR: PROCYON BIOPHARMA INC. ASE SYMBOL: PBP SEPTEMBER 21, 1999 Procyon BioPharma Inc. Announces Appointment of Hans Mader as President and CEO: Company Moves Head Office to Montreal LONDON, ONTARIO--Dr. Chandra Panchal, Chairman of the Board of Procyon BioPharma Inc., announced today the appointment of Mr. Hans Mader as President and CEO. The Company also announced that it will be moving its head office to Montreal in order to benefit from the synergies of the vibrant biotech environment in the region. Mr. Mader has had many years experience with leading firms in the pharmaceutical industry in Canada, the U.S.A and Europe, most recently as the Head of Global Marketing Services at the Head Office of Novartis Pharma in Switzerland. Prior to his appointment there, he directed the merger of Ciba-Geigy and Sandoz in Canada and served as CEO of Sandoz and then as President and CEO of the resulting company, Novartis Pharmaceuticals Inc. Canada, with $300 million a year in sales and approximately 1,000 employees. While at Novartis, Mr. Mader succeeded in attracting major research projects and investments to Canada. At Sandoz, Mr. Mader also held senior marketing positions and successfully launched several new products as well as innovative marketing campaigns. Mr. Mader is a member of the Board of Canada's Research-Based Pharmaceutical Companies (formerly the Pharmaceutical Manufacturers' Association of Canada) and active in a number of its committees. "Procyon has reached a state in its development where it believes the experience of a seasoned pharmaceutical executive can take the Company to the next level of commercial development and partnering. We are delighted that Hans Mader has decided to join us to take on this challenge," stated Dr. Panchal who has served as the Company's Chairman, President and CEO since co-founding it in 1989. Dr. Panchal will take on the position of Executive Vice-President and Chief Scientific Officer in order to devote his full attention to the development of the company's technologies and to the identification of new technology platforms and international collaborations. Mr. Mader's appointment becomes effective as of today. "In returning to Canada, I have had the opportunity to look at several biotech companies," he said, "and I have chosen Procyon because of its remarkably innovative technologies for the treatment of cancer and because it represents a well balanced portfolio with products that are close to market as well as proprietary R&D platforms for future growth. My goal is to commercialize this Company's excellent scientific pipeline," he added. Procyon's laboratory facilities will be located in Montreal's Biotechnology Research Institute and its administrative offices will be situated in the West Island of Montreal. Scientific and administrative staff levels will remain approximately the same and some active research collaboration in London, Ont. will be maintained. Procyon BioPharma Inc. is a publicly listed, biopharmaceutical company focused principally on advancing two powerful platform technologies that have the potential to treat, diagnose and prevent cancer. Procyon's Prostate Secretory Protein (PSP94) is a naturally occurring human protein that has the potential to treat prostate cancer by inhibiting abnormal prostate cell growth. Antinuclear Autoantibodies (ANAs) bind specifically to multiple cancer cell types strongly enhancing the immune response to cancer cells. Procyon also has two late-stage products in its pipeline: FIBROSTAT(TM), a topical cream for the management of newly formed scars following surgery or burns and COLOPATH(TM), a rapid, non-invasive screening test for colorectal cancer. Procyon's shares trade on the Alberta Stock Exchange under the ticker symbol, PBP. The Alberta Stock Exchange has neither approved nor disapproved of the information contained herein. Come on people,if this is not good news then I am very bewildered,welcome Mr.Mader and continued success to Dr.Panchal.